Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Emapalumab by Swedish Orphan Biovitrum for Cytopenia: Likelihood of Approval
Emapalumab is under clinical development by Swedish Orphan Biovitrum and currently in Phase II for Cytopenia. According to GlobalData, Phase...
Data Insights
Emapalumab by Swedish Orphan Biovitrum for Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease): Likelihood of Approval
Emapalumab is under clinical development by Swedish Orphan Biovitrum and currently in Phase III for Systemic-Onset Juvenile Idiopathic Arthritis (Still...